
==== Front
Ann Lab Med
Ann Lab Med
Annals of Laboratory Medicine
2234-3806
2234-3814
Korean Society for Laboratory Medicine

10.3343/alm.2024.0221
alm-44-6-621
Letter to the Editor
Diagnostic Genetics
Aberrant Splicing in PKD2 in a Family of Korean Patients With Autosomal Dominant Polycystic Kidney Disease
https://orcid.org/0000-0002-0066-5390
Yoon Soo-Young M.D., Ph.D. 1
https://orcid.org/0000-0002-0066-5390
Kim Jin Sug M.D., Ph.D. 1
https://orcid.org/0000-0002-0066-5390
Park Kyung Sun M.D., Ph.D. 23
1 Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Korea
2 Department of Laboratory Medicine, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Korea
3 Rare Disease Center, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Korea
Corresponding author: Jin Sug Kim, M.D., Ph.D. Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Medical Center,26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea E-mail: jinsuk0902@khu.ac.kr Co-Corresponding author: Kyung Sun Park, M.D., Ph.D. Department of Laboratory Medicine,Kyung Hee University College of Medicine, Kyung Hee University Medical Center, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea E-mail: drkyungsun@gmail.com
1 11 2024
22 8 2024
22 8 2024
44 6 621624
3 5 2024
4 7 2024
8 8 2024
© Korean Society for Laboratory Medicine
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Kyung Hee University http://dx.doi.org/10.13039/501100002597 KHU-20233269
==== Body
pmcBody

Dear Editor,

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disease leading to end-stage kidney disease [1]. ADPKD mainly arises from genetic alternations in the PKD1 and PKD2 genes, accounting for approximately 75% and 15% of cases, respectively [2]. In comparison to PKD1-related ADPKD, PKD2-related ADPKD presents with milder symptoms and is often diagnosed incidentally through imaging or urologic events at a later age, typically after the fourth decade of life [2].

We report the case of a family of patients with ADPKD caused by aberrant splicing in PKD2, from which a 56-yr-old woman presented with multiple renal and hepatic cysts incidentally found on an abdominal ultrasonography performed for a health check-up in April 2019. The institutional review board- of Kyung Hee University Medical Center, Seoul, Korea, approved this study (approval No. 2023-07-078). The patient had a height of 153 cm, weight of 55 kg, and body mass index of 23.5 kg/m2, and had been taking medications for hypertension and hyperlipidemia for 6 yrs. Laboratory investigations showed a normal serum creatinine level (0.82 mg/dL, reference range: 0.34–1.08 mg/dL) and an estimated glomerular filtration rate of 83.4 mL/min/1.73m2. The liver function test was in the normal range, and no specific findings were observed in the urine test. Abdominal computed tomography showed numerous bilateral renal cysts and hepatic cysts of varying sizes (Fig. 1A). The kidneys were enlarged, with a total kidney volume of 563.2 cm3. The mother, brother, and son of the patient had a history of multiple renal and hepatic cysts (Fig. 1B). Her mother also had a history of cerebral hemorrhage (Fig. 1).

To make a definitive diagnosis of ADPKD, the patient and her son underwent clinical exome sequencing (Fig. 1C). Both individuals had the same heterozygous intronic variant at the acceptor motif, NM_000297.4:c.2020-5A>G, in PKD2. This variant has not been reported in the general population (https://gnomad.broadinstitute.org/) or other patients with ADPKD. Although reported once in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/, last accessed on April 18, 2024), it was classified as uncertain significance (review status: one star) because of insufficient evidence. We predicted the pathogenicity of this variant using SpliceAI [3] and observed a significant change in the acceptor score at position c.2020, decreasing from 0.99 to 0.24 (Delta score: 0.76) (Fig. 2A). In addition, at position c.2020-4, we observed a substantial change in the acceptor score from 0 to 1 (Delta score: 1.00) (Fig. 2A). In summary, this intronic variant is predicted to shift the acceptor site by +1 base pair (bp) instead of causing the typical exon skipping seen with intronic variants near exon boundaries. This shift may potentially induce a premature termination codon (PTC) (Fig. 2).

Therefore, we extracted DNA and RNA from the proband to determine whether there were changes in the RNA sequence as predicted using SpliceAI [3]. We confirmed the presence of the intronic variant using Sanger sequencing (Fig. 2B). Additionally, reverse transcription PCR revealed that, unlike the single band observed in the control (299 bp), our patient had two distinct bands of different sizes (299 bp and 303 bp) (Fig. 2C). Through targeted RNA sequencing, we confirmed that, as predicted using SpliceAI [3], the acceptor site was shifted by +1 bp (NM_000297.4:r.2019_2020insacag), leading to the eventual induction of PTC (p.(Asn674Thrfs*10)) (Fig. 2D) and likely triggering nonsense-mediated decay (NMD) [4].

However, because of the lack of research on NMD efficiency for PKD2, we predicted the structural changes in the mutant PKD2 protein, assuming that the mRNA resulting from this intronic variant might escape NMD and undergo translation. To this end, we compared and analyzed the PKD2 protein structure (yellow) predicted using AlphaFold2 [5] based on the mutant sequence with the canonical PKD2 structure (purple) using ChimeraX Matchmaker (Fig. 2E–2F) [6]. Comparing the canonical and mutant protein structures suggested that some regions would have different structures despite having the same sequence (e.g., residues 1–200). Notably, the region spanning residues 750–785 is crucial for Ca2+ binding (https://www.ebi.ac.uk/interpro/protein/UniProt/Q13563/) and PKD2 channel activity regulation. However, in the mutant protein, this region is not translated, which is predicted to significantly affect protein function [7].

According to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology guidelines [8] and ClinGen recommendations (https://clinicalgenome.org/) [9, 10], this intronic variant was classified as likely pathogenic based on the evidence PVS1, PM2_Supporting, and PP1_Supporting. This case, where an intronic variant located outside the ±1 or 2 dinucleotide positions of the donor/acceptor sites induces a PTC owing to intron retention rather than exon skipping [11], highlights the significance of splicing prediction in interpreting intronic variants.

ACKNOWLEDGEMENTS

We thank Eun Chong Byun, RN (Rare Disease Center, Kyung Hee University Medical Center) and Haeran Jin, MT (Department of Laboratory Medicine, Kyung Hee University Medical Center) for their dedicated efforts in conducting the patient’s family analysis and additional confirmatory tests.

Fig. 1 The CT findings, pedigree analysis, and next-generation sequencing results of the proband with ADPKD. (A) Multiple renal cysts were identified in the transverse plane of the CT scan. Multiple hepatic cysts were observed in the transverse plane of the CT scan. Multiple renal and hepatic cysts were visible in the coronal plane of the CT scan. (B) Pedigree of the proband (III-2) with ADPKD. The mother (II-7), younger brother (III-4), and son (IV-2) of the proband were diagnosed as having multiple renal or hepatic cysts. The same PKD2 variant was identified in both the proband and her son. (C) Results of next-generation sequencing testing related to ADPKD for the proband and son. The same heterozygous variant in PKD2 (NM_000297.4:c.2020-5A>G) was found in the proband and son.

Abbreviations: CT, computed tomography; ADPKD, autosomal dominant polycystic kidney disease.

Fig. 2 Additional confirmatory results for interpreting the genetic variant identified in the proband. (A) The pathogenicity of NM_000297.4:c.2020-5A>G was predicted using SpliceAI [3]. It was predicted that, because of this intronic variant, acceptor loss would occur at the +5 bp position (with a change from 0.99 to 0.24, delta score of 0.76), and acceptor gain would occur at the +1 bp position (with a change from 0 to 1, delta score of 1). The SpliceAI score was visualized with some modifications using MobiDetails (https://mobidetails.iurc.montp.inserm.fr/MD/) (B) Sanger sequencing was conducted to reassess the presence of the intronic variant in the proband, and the results confirmed its presence. (C) Agarose gel electrophoresis of a targeted reverse transcription PCR product, showing a single band of 299 bp in the control and two bands of different sizes (299 bp and 303 bp) in the proband. (D) Targeted RNA sequencing revealed a change in the 299-bp RNA sequence (NM_000297.4:r.2019_2020insacag), which is anticipated to induce a PTC (p.(Asn674Thrfs*10)). The boundary between exons 9 and 10 in the RNA sequence is marked with a vertical dashed line on the chromatogram. (E) PKD2 structure (yellow) predicted using AlphaFold2 [5] based on the mutant sequence compared with the canonical PKD2 structure (purple) using ChimeraX Matchmaker [6]. Regions predicted to have the same structure based on RMSD in MatchMaker are highlighted in green. (F) The MatchMaker Multalign viewer displays the RMSD values (Cα RMSD) of the pairwise sequence alignment between the canonical and mutant sequences as the height of the histogram bars. Matched residues are highlighted with green boxes.

Abbreviations: bp, base pair; PTC, premature termination codon; RMSD, root mean square deviation.

AUTHOR CONTRIBUTIONS

Park KS and Kim JS had full access to all the data in the study and take responsibility for data integrity and the accuracy of data analysis. Conceptualization: Yoon SY, Park KS, and Kim JS; Methodology: Yoon SY, Park KS, and Kim JS; Investigation: Yoon SY, Park KS, and Kim JS; Visualization: Yoon SY, Park KS, and Kim JS; Supervision: Yoon SY, Park KS, and Kim JS; Writing – original draft: Yoon SY, Park KS, and Kim JS; Writing – review & editing: Yoon SY, Park KS, and Kim JS. All authors have read and approved the final manuscript. The corresponding authors attest that all listed authors meet the authorship criteria and that no other author meeting the criteria has been omitted.

CONFLICTS OF INTEREST

None declared.

RESEARCH FUNDING

This work was supported by a grant from Kyung Hee University in 2023 (KHU-20233269).
==== Refs
References

1 Borrego Utiel FJ Espinósa Hernandez M 2023 How to estimate kidney growth in patients with autosomal dominant polycystic kidney disease J Am Soc Nephrol 34 944 50 10.1681/ASN.0000000000000130 36995133
2 Lanktree MB Haghighi A di Bari I Song X Pei Y 2021 Insights into autosomal dominant polycystic kidney disease from genetic studies Clin J Am Soc Nephrol 16 790 9 10.2215/CJN.02320220 32690722
3 Jaganathan K Kyriazopoulou Panagiotopoulou S McRae JF Darbandi SF Knowles D Li YI 2019 Predicting splicing from primary sequence with deep learning Cell 176 535 48 e24 10.1016/j.cell.2018.12.015 30661751
4 Litchfield K Reading JL Lim EL Xu H Liu P Al-Bakir M 2020 Escape from nonsense-mediated decay associates with anti-tumor immunogenicity Nat Commun 11 3800 10.1038/s41467-020-17526-5 5361db97aec7487d9e4b4732b41ccecf 32733040
5 Jumper J Evans R Pritzel A Green T Figurnov M Ronneberger O 2021 Highly accurate protein structure prediction with AlphaFold Nature 596 583 9 10.1038/s41586-021-03819-2 34265844
6 Meng EC Goddard TD Pettersen EF Couch GS Pearson ZJ Morris JH 2023 UCSF ChimeraX: tools for structure building and analysis Protein Sci 32 e4792 10.1002/pro.4792 37774136
7 Shen PS Yang X DeCaen PG Liu X Bulkley D Clapham DE 2016 The structure of the polycystic kidney disease channel PKD2 in lipid nanodiscs Cell 167 763 73 e11 10.1016/j.cell.2016.09.048 27768895
8 Richards S Aziz N Bale S Bick D Das S Gastier-Foster J 2015 Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet Med 17 405 24 10.1038/gim.2015.30 25741868
9 Walker LC Hoya M Wiggins GAR Lindy A Vincent LM Parsons MT 2023 Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: recommendations from the ClinGen SVI Splicing Subgroup Am J Hum Genet 110 1046 67 10.1016/j.ajhg.2023.06.002 37352859
10 Biesecker LG Byrne AB Harrison SM Pesaran T Schaffer AA Shirts BH 2024 ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification Am J Hum Genet 111 24 38 10.1016/j.ajhg.2023.11.009 38103548
11 Kim J Yu J Lee S Kim S Lee IS Lee W 2024 Reverse transcription-PCR-based Sanger sequencing-confirmed exon-skipping effect of a novel GEN1 intronic variant (c.1408+4A>G) Ann Lab Med 44 188 91 10.3343/alm.2023.0163 37840312
